RGCC Test for Cancer Diagnostics
Research Genetics Cancer Center (R.G.C.C.) Group was established in 2004 by Dr. Ioannis Papasotiriou. The company is a pioneering, innovative organization working in the fields of medical genetics and, in particular, cancer genetics, chemosensitivity, and chemo-resistance testing and in Research and Development within the pharmaceutical industry via RGCC Pharma Ltd.
The company headquarters are in Switzerland, and the brand new, state-of-the-art laboratories in Northern Greece are equipped with the most up-to-date technological, advanced, and innovative equipment.
RGCC isolates the CTCs using a technology called flow cytometry in order to obtain a sample of 97-99% pure cells that are 99% viable for further testing, such as molecular analysis, immunophenotyping, gene expression assays, and sensitivities to various agents. There are numerous new labs arriving on the CTC testing scene using various technologies, mostly providing only CTC counts and basic gene expression data.
RGCC Group offers general assays for CTCs and for specific cancers including breast, colorectal, prostate, lung, melanoma, and sarcomas. The test is performed from a simple blood sample and results are completed in 7-10 days.
Why Should I Consider the RGCC for Cancer Treatment?
At Cancer Center For Healing, we offer you personalized cancer care by testing your genetics through an R.G.C.C. blood analysis test. R.G.C.C. stands for Research Genetic Cancer Center which is an international company utilized by 14 countries worldwide. The Cancer Center for Healing is one of the few cancer treatment centers in the U.S.A using this type of cancer testing!
This blood test analyzes circulating tumor cells and cancer stem cells through targeted test results. The results from the test help us recommend the best type of chemo that will respond to your cancer and also what natural treatments have the likelihood of working for you. We are then able to tailor cancer treatment plans for our patients to enhance treatment outcomes.
R.G.C.C. analysis has revolutionized how we care for our cancer patients. Over the past nine years, more than 300 physicians worldwide have utilized the R.G.C.C. personalized cancer care analysis with their patients and have seen tremendous strides in cancer survival.
Here at Cancer Center For Healing we offer you personalized cancer care by testing your genetics through R.G.C.C.-USA, LLC’s blood analysis test. R.G.C.C. is an international company utilized by 14 International Countries. This blood test analyzes circulating tumor cells and cancer stem cells through targeted test results.
Cancer Center For Healing is then able to tailor cancer treatment plans for our patients to enhance treatment outcomes. R.G.C.C. analysis has revolutionized how we care for our cancer patients. Over the past nine years, more than 300 physicians worldwide have utilized the R.G.C.C. personalized cancer care analysis with their patients and have seen tremendous strides in cancer survival.
The R.G.C.C. tests are designed to assess which types of cancer treatments will be most effective for a specific person and type of cancer.
R.G.C.C. Tests Available for Cancer Diagnostics
This test will report only the number of Circulating Cancer Tumor Cells (CTCs). It does not include any other information concerning the CTCs or Circulating Cancer Stem Cells (CSCs).
This test will report the number of CTCs, any positive CSCs, and the immunophenotype of these cells––one of the most useful screening tests.
Note: It is recommended to order both the OncoTrace and Onconomics Plus simultaneously. If no CTCs are found on the OncoTrace, the Onocnomics Plus will not proceed and will be refunded. If CTCs are found, the lab will continue to the Onconomics Plus automatically.
This test is a tailor-made test for a specific type of malignancy such as breast cancer (Oncotrail for Breast), prostate (Oncotrail for Prostate), and so on.
This test includes only markers relative to a specific type of malignancy, making the test for follow-up control patient management.
This includes the chemosensitivity/chemoresistance assessment for cytotoxic drugs, monoclonal antibodies, and small molecules that inhibit specific targets eg. (TKI, etc.). No natural substances were tested.
This test strikes right at the heart of what RGCC does uniquely and best. This test provides thorough, targeted information about what drugs, treatments, and natural remedies might be best suited for particular cancer.
It does this by employing two procedures, epigenetic analysis, and viability analysis; the test takes specific drugs and remedies and tests for direct effects of certain treatments, stimulation of the immune system, and inhibiting signals in cancer cells that stimulate their growth.
This approach allows your doctors to narrow down what options might be better for you than others. There is also a simpler but similar test on offer, the Onconomics RGCC, which provides some but not all of the same analysis, excluding the testing for natural treatments found in the Onconomics Plus RGCC.
As we take a holistic approach to patient health, we recommend the Onconomics Plus RGCC, as it provides you with more thoroughly analyzed options for your treatment regimen.
Note: It is recommended to order both the OncoTrace and Onconomics Plus simultaneously. If no CTCs are found on the OncoTrace, the Onocnomics Plus will not proceed and will be refunded. If CTCs are found, the lab will automatically continue to the Onconomics Plus.
This test includes only the assessment of natural substances and plant extracts for any anticancer potency. No chemotherapeutic agents were tested, and no tumor suppressor genes were tested.
This is not a test, rather the patient’s blood is used to make the SOT by using the mRNA to induce certain gene expressions. SOT therapy can induce apoptosis in the CTCs and all primary and metastatic tumors. The SOT can also be used for viruses.
We use RGCC to test for circulating cancer cells but also to see what natural drugs will work to kill the cancer cells.
If you have been diagnosed with cancer, chances are you have been exposed to various medical tests. No patient will ever receive the same set of tests, but we commonly prescribe one particular set of tests for cancer detection and treatment plan formation: RGCC.
RGCC stands for “Research Genetics Cancer Center.” The RGCC is a medical testing company—headquartered in Switzerland with facilities worldwide—that specializes in cutting-edge genetic tests to help diagnose and determine effective treatment plans for medicine. Many cancer tests stop at diagnosis without venturing into treatment, which is where RGCC stands out amongst its competition.
RGCC’s test suite can identify key characteristics of cancer, including responsiveness to chemotherapy and the likelihood of spreading to a specific site in the body.
Their suite of tests provides thorough, helpful information that few other tests can provide, and as such, they are critical to our diagnosis and treatment regimens.
More simply, the RGCC tests are designed to detect cancer cells and help us get a complete picture of what those cells are and, by extension, what treatments they might best respond to.
Many cancer tests cannot give in-depth information about the genotype and details of cancer the same way RGCC tests can; that means that without RGCC tests, doctors may be operating based on more limited information. Here’s a little more information about specific RGCC tests that may be offered to our patients depending on their specific cancer diagnosis:
If you seek treatment with our facility, it’s nearly sure we will consult with you about the possibility of utilizing RGCC tests to diagnose better and treat your cancer. The company provides a handy and informative set of options that allow us to give the best treatment possible to all our patients.
Schedule A RGCC Test & Consultation on Lab Results:
Call (949) 581-HOPE (4673), email us at email@example.com , or chat with us live to schedule your appointment. We are here to answer any questions and to help you schedule a personal consultation with an Integrative Cancer Specialist.